RAPT Therapeutics (NASDAQ: RAPT) share price is rallying after the company reported positive topline results from Phase 1b trial of RPT193 Monotherapy in atopic dermatitis.
RAPT said that patients with moderate-to-severe AD who received RPT193 showed a 36.3% improvement from baseline in the Eczema Area and Severity Index (EASI) after four weeks of treatment.
In the two weeks after the treatment ended, the group treated with RPT193 showed continued improvement and further separation from placebo with a 53.2% improvement in EASI at the six-week time point compared to 9.6% in the placebo group.
There were no serious or adverse events, and RAPT plans to advance RPT193 to a Phase 2b clinical trial and is also planning a Phase 2a study in asthma. The company said it intends to report additional data and analyses in a future publication or an upcoming medical conference.
“These data strongly support the potential of RPT193 as a safe, once-daily, oral treatment for patients with atopic dermatitis which would be an attractive therapeutic alternative ahead of injectable drugs,” said Brian Wong, President and CEO of RAPT Therapeutics.
“We look forward to advancing RPT193 to a Phase 2b trial in atopic dermatitis and a Phase 2a trial in asthma.”
RAPT Therapeutics share price is currently trading 99% above Friday's close at $36.96.
Should You Invest in RAPT Therapeutics Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now